Nan LiinObvious VenturesInvesting in Iterative ScopesBringing personalized medicine to gastroenterologyAug 3, 2021Aug 3, 2021
Nan LiinObvious VenturesTo RXRX and BeyondTheir IPO is another milestone along a longer journey for Recursion.Apr 16, 20211Apr 16, 20211
Nan LiinObvious VenturesPromoting Meera Clark to PrincipalLeveling up the Obvious Investment TeamMar 8, 20214Mar 8, 20214
Nan LiinObvious VenturesInvesting in DexterityFreeing robots from cages, and pioneering the next generation of industrial roboticsJul 21, 20201Jul 21, 20201
Nan LiinObvious VenturesInvesting in Inato95% of the eligible patients for a clinical trial are never considered. It’s time for a transformation.Feb 4, 2020Feb 4, 2020
Nan LiinWorld PositiveThe New BiologyA counterintuitive approach to biological design challengesOct 29, 2019Oct 29, 2019
Nan LiinObvious VenturesInvesting in LabGeniusAdvancing protein therapies using computational biologyOct 23, 2019Oct 23, 2019
Nan LiinWorld PositiveIndustrial IQ: Where High Tech Meets Low TechTech is breaking out of the Silicon Valley sandbox, transforming traditional, trillion-dollar industries in the process.Apr 30, 20191Apr 30, 20191
Nan LiinObvious VenturesOur Investment in DarwinAIDriving towards a safe, high performance future for AISep 25, 2018Sep 25, 2018
Nan LiinObvious VenturesWelcome Will Dzierson!Designer in Residence at Obvious VenturesJul 17, 2018Jul 17, 2018